

# Liver Thrombosis Program at Mount Sinai

## Publications Authored by Members of the Liver Thrombosis Program Multi-disciplinary Team

Ibrahim U, Petrone GEM, [Mascarenhas J](#), Keyzner A. Peritransplantation Use of Ruxolitinib in Myelofibrosis. *Biol Blood Marrow Transplant* 2020:S1083-8791(20)30507-3. doi: 10.1016/j.bbmt.2020.08.015. PMID: 32818555. Online ahead of print.

Chowdhury O, O'Sullivan J, Barkas N, Wang G, Buck G, Hamblin A, Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, McMullin MF, Zhong J, Gale RP, Mead AJ; RESUME trialists: [Mascarenhas J](#), et al. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. *Leukemia* 2020 Aug 7. doi: 10.1038/s41375-020-0979-6. PMID: 32770086. Online ahead of print.

[Naymagon L](#), [Tremblay D](#), Zubizarreta N, Moshier E, [Schiano T](#), [Mascarenhas J](#). Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation. *J Thromb Thrombolysis* 2020;50:652-660 ( PMID: 32034618).

Venugopal S, [Mascarenhas J](#), Steensma DP. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. *Blood Rev* 2020 Jul 23:100735. doi: 10.1016/j.blre.2020.100735. PMID: 32736878. Online ahead of print.

[Tremblay D](#), Schwartz M, Bakst R, [Patel R](#), [Schiano T](#), Kremyanskaya M, [Hoffman R](#), [Mascarenhas J](#). Modern management of splenomegaly. *Ann Hematol* 2020;99:1441-1451. PMID: 32417942.

Marcellino BK, Verstovsek S, [Mascarenhas J](#). The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. *Clin Lymphoma Myeloma Leuk* 2020;20:415-421. PMID: 32199764.

Georges A, Albuisson J, Berrandou T, Dupré D, Lorthioir A, D'Escamard V, Di Narzo AF, [Kadian-Dodov D](#), Olin JW, Warchol-Celinska E, Prejbisz A, Januszewicz A, Bruneval P, Baranowska AA, Webb TR, Hamby SE, Samani NJ, Adlam D, Fendrikova-Mahlay N, Hazen S, Wang Y, Yang ML, Hunker K, Combaret N, Motreff P, Chédid A, Fiquet B, Plouin PF, Mousseaux E, Azarine A, Amar L, Azizi M, Gornik HL, Ganesh SK, Kovacic JC, Jeunemaitre X, Bouatia-Naji N. Rare Loss-of-function Mutations of PTGIR are enriched in Fibromuscular Dysplasia. *Cardiovasc Res* 2020 Jun 12:cvaa161. doi: 10.1093/cvr/cvaa161. PMID: 32531060. Online ahead of print.

[Mascarenhas J](#), Mehra M, He J, Potluri R, Loeffgren C. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. *J Med Econ* 2020;23:721-727. PMID: 32159402.

Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O'Connell C, Shammo J, Fleischman AG, Scherber RM, Mesa R, Yacoub A, Perkins C, Meckstroth S, Behlman L,

Chiaramonte M, Salehi M, Ziadkhanpour K, Nguyen H, Siwoski O, Hung AK, Janania Martinez M, Nguyen J, Patel S, Kollipara R, Dave A, Randall M, Grant M, Harrison M, Fernandez Soto P,

[Tremblay D](#), [Hoffman R](#), Moshier E, [Mascarenhas J](#). Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. *Blood* 2020;135:1696-1703. PMID: 32107559.

Coltoff A, Mesa R, Gotlib J, Shulman J, Rampal RK, Siwoski O, Yacoub A, Moliterno A, Yang A, Braunstein E, Gerds AT, Hobbs GS, Winton EF, Goel S, Wadleigh M, [Tremblay D](#), Moshier E, [Mascarenhas J](#). Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. *Clin Lymphoma Myeloma Leuk* 2020:S2152-2650(20)30265-2. doi: 10.1016/j.clml.2020.05.019. PMID: 32624445. Online ahead of print.

[Tremblay D](#), [Naymagon L](#), Troy K, Cromwell C, Edwards C, [Schiano T](#), Kremyanskaya M, [Mascarenhas J](#). The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis. *Blood Coagul Fibrinolysis* 2020;31:213-218. PMID: 32101880.

[Tremblay D](#), [Mascarenhas J](#). Novel Therapies in Polycythemia Vera. *Curr Hematol Malig Rep* 2020;15:133-140. PMID: 32034662.

[Mascarenhas J](#). Interferon- $\alpha$ : alternative first- or second-line therapeutic option for polycythaemia vera. *Lancet Haematol* 2020;7:e178-e179. PMID: 32014126.

[Tremblay D](#), King A, Li L, Moshier E, Coltoff A, Koshy A, Kremyanskaya M, [Hoffman R](#), Mauro MJ, Rampal RK, [Mascarenhas J](#). Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. *Leuk Lymphoma* 2020;61:660-667. PMID: 31711337.

[Naymagon L](#), [Tremblay D](#), Zubizarreta N, Moshier E, Naymagon S, [Mascarenhas J](#), [Schiano T](#). The natural history, treatments, and outcomes of portal vein thrombosis in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2020 Mar 18;izaa053. doi: 10.1093/ibd/izaa053. PMID: 32185400. Online ahead of print.

Zhou S, [Tremblay D](#), [Hoffman R](#), Kremyanskaya M, Najfeld V, Li L, Moshier E, [Mascarenhas J](#). Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms. *Acta Haematol* 2020 Mar 11:1-9. doi: 10.1159/000506146. PMID: 32160610. Online ahead of print.

[Naymagon L](#), [Tremblay D](#), Zubizarreta D; Moshier E, Troy K, [Schiano T](#), [Mascarenhas J](#). The efficacy and safety of direct oral anticoagulants in non-cirrhotic portal vein thrombosis. *Blood Adv* 2020;4:655-666. PMID: 32078681.

[Naymagon L](#), [Tremblay D](#), [Schiano T](#), [Mascarenhas J](#). The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes. *J Thromb Thrombolysis* 2020;49:325-331. PMID: 31493290.

Tremblay D, Vogel A, Moshier E, Hoffman R, Kremyanskaya M, Zhou S, Schiano T, Mascarenhas J. Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience. *Eur J Haematol* 2020;104:72-73. PMID: 31587352.

Olin JW, Di Narzo AF, d'Escamard V, Kadian-Dodov D, Cheng H, Georges A, King A, Thomas A, Barwari T, Michelis KC, Bouchareb R, Bander E, Anyanwu A, Stelzer P, Filsoufi F, Florman S, Civelek M, Debette S, Jeunemaitre X, Björkegren JLM, Mayr M, Bouatia-Naji N, Hao K, Kovacic JC. A plasma proteogenomic signature for fibromuscular dysplasia. *Cardiovasc Res* 2020;116:63-77. PMID: 31424497.

Sapre M, Tremblay D, Wilck E, James A, Leiter A, Coltoff A, Koshy AG, Kremyanskaya M, Hoffman R, Mascarenhas JO, Gallagher EJ. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. *Sci Rep* 2019;9:16609. PMID: 31719581.

Ronner L, Mascarenhas J, Moshier EL. Response to meta-analysis of leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera. *Blood Adv* 2019;3:3010-3012. PMID: 31648311.

Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenson D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. *Blood* 2019;134:1498-1509. PMID: 31515250.

Cimen Bozkus C, Roudko V, Finnigan JP, Mascarenhas J, Hoffman R, Iancu-Rubin C, Bhardwaj N. Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. *Cancer Discov* 2019;9:1192-1207. PMID: 31266769.

Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, Mesa R, Petersen B, Farnoud N, Najfeld V, Rampal R, Dueck A, Hoffman R. Oral idasanutlin in patients with polycythemia vera. *Blood* 2019;134:525-533. PMID: 31167802.

Marcellino B, Mascarenhas J. Management of advanced phase myeloproliferative neoplasms. *Clin Adv Hematol Oncol* 2019;17:405-411. PMID: 31449507.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. *Biol Blood Marrow Transplant* 2019;25:1142-1151. PMID: 30625392.

Levavi H, Tripodi J, Marcellino B, Mascarenhas J, Jones AV, Cross NCP, Gruenstein D, Najfeld V. A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. *Acta Haematol* 2019;142:105-112. PMID: 31063994.

Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, Bruno RM, de Leeuw P, Fendrikova-Mahlay N, Froehlich J, Ganesh SK, Gray BH, Jamison C, Januszewicz A, Jeunemaitre X, [Kadian-Dodov D](#), Kim ES, Kovacic JC, Mace P, Morganti A, Sharma A, Southerland AM, Touzé E, van der Niepen P, Wang J, Weinberg I, Wilson S, Olin JW, Plouin PF. First International Consensus on the diagnosis and management of fibromuscular dysplasia. *Vasc Med* 2019;24:164-189. PMID: 30648921.

[Mascarenhas J](#), Baer MR, Kessler C, Hexner E, [Tremblay D](#), Price L, Sandy L, Weinberg R, Pahl H, Silverman LR, Goldberg JD, Kosiorek H, Dueck AC, [Hoffman R](#). Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. *Leuk Lymphoma* 2019;60:1343-1345. PMID: 30668266.

Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, [Mascarenhas JO](#), [Hoffman R](#). Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. *Biol Blood Marrow Transplant* 2019;25:256-264. PMID: 30205231.

Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, Bruno RM, De Leeuw P, Fendrikova-Mahlay N, Froehlich J, Ganesh SK, Gray BH, Jamison C, Januszewicz A, Jeunemaitre X, [Kadian-Dodov D](#), Kim ESH, Kovacic JC, Mace P, Morganti A, Sharma A, Southerland AM, Touzé E, Van der Niepen P, Wang J, Weinberg I, Wilson S, Olin JW, Plouin PF; Working Group 'Hypertension and the Kidney' of the European Society of Hypertension (ESH) and the Society for Vascular Medicine (SVM). First international consensus on the diagnosis and management of fibromuscular dysplasia. *J Hyperten* 2019;37:229-252. PMID: 30640867.

[Tremblay D](#), Putra J, Vogel A, Winters A, [Hoffman R](#), [Schiano T](#), [Fiel M](#), [Mascarenhas J](#). The implications of liver biopsy results in patients with myeloproliferative neoplasms being treated with Ruxolitinib. *Case Rep Hematol* 2019;2019:3294046. PMID: 30723558.

Adlam D, Olson TM, Combaret N, Kovacic JC, Iismaa SE, Al-Hussaini A, O'Byrne MM, Bouajila S, Georges A, Mishra K, Braund PS, d'Escamard V, Huang S, Margaritis M, Nelson CP, de Andrade M, [Kadian-Dodov D](#), Welch CA, Mazurkiewicz S, Jeunemaitre X; DISCO Consortium, Wong CMY, Giannoulatou E, Sweeting M, Muller D, Wood A, McGrath-Cadell L, Fatkin D, Dunwoodie SL, Harvey R, Holloway C, Empana JP, Jouven X; CARDIoGRAMPlusC4D Study Group, Olin JW, Gulati R, Tweet MS, Hayes SN, Samani NJ, Graham RM, Motreff P, Bouatia-Naji N. Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. *J Am Coll Cardiol* 2019;73:58-66. PMID: 30621952.

Marcellino BK, [Hoffman R](#), Tripodi J, Lu M, Kosiorek H, [Mascarenhas J](#), Rampal RK, Dueck A, Najfeld V. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. *Blood Adv* 2018;2:3581-3589. PMID: 30563882.

Rampal RK, [Mascarenhas JO](#), Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML,

Levine RL, Mesa RA, Dueck AC, Goldberg JD, [Hoffman R](#). Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. *Blood Adv* 2018;2:3572-3580. PMID: 30563881.

[Tremblay D](#), [Mascarenhas J](#). Pacritinib to treat myelofibrosis patients with thrombocytopenia. *Expert Rev Hematol* 2018;11:707-714. PMID: 30001163.

Al-Fayoumi S, Hashiguchi T, Shirakata Y, [Mascarenhas J](#), Singer JW. Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. *J Exp Pharmacol* 2018;10:9-17. PMID: 29785143.

[Mascarenhas J](#), [Hoffman R](#), Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncol* 2018;4:652-659. PMID: 29522138.

Shreenivas A, [Mascarenhas J](#). Emerging drugs for the treatment of Myelofibrosis. *Expert Opin Emerg Drugs* 2018;23:37-49. PMID: 29480036.

[Kadian-Dodov D](#), Gornik HL, Gu X, Froehlich J, Bacharach JM, Chi YW, Gray BH, Jaff MR, Kim ES, Mace P, Sharma A, Kline-Rogers E, White C, Olin JW. Dissection and Aneurysm in Patients With Fibromuscular Dysplasia: Findings From the U.S. Registry for FMD. *J Am Coll Cardiol* 2016;68:176-85.

Bercu ZL, Sheth SB, Noor A, [Lookstein RA](#), Fischman AM, Nowakowski FS, Kim E, [Patel RS](#). Percutaneous mesocaval shunt creation in a patient with chronic portal and superior mesenteric vein thrombosis. *Cardiovasc Intervent Radiol* 2015;38:1316-9. PMID: 25189666.

Michelis KC, Olin JW, [Kadian-Dodov D](#), d'Escamard V, Kovacic JC. Coronary artery manifestations of fibromuscular dysplasia. *J Am Coll Cardiol* 2014;64:1033-46. PMID: 25190240.

Mayer JE, [Schiano TD](#), Fiel MI, [Hoffman R](#), [Mascarenhas JO](#). An association of myeloproliferative neoplasms and obliterative portal venopathy. *Dig Dis Sci* 2014;59:1638-41. PMID: 24474573.

[Kadian-Dodov DL](#), van der Zee SA, Scott SA, Peter I, Martis S, Doheny DO, Rothlauf EB, Lubitz SA, Desnick RJ, Halperin JL. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects. *Vasc Med* 2013;18:290-7. PMID: 24029542.

Sozer S, [Fiel MI](#), [Schiano T](#), Xu M, [Mascarenhas J](#), [Hoffman R](#). The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. *Blood* 2009;113:5246-9. PMID: 19293426.

Pintucci G, Saunders PC, Gulkarov I, Sharony R, [Kadian-Dodov DL](#), Bohmann K, Baumann FG, Galloway AC, Mignatti P. Anti-proliferative and anti-inflammatory effects of topical MAPK inhibition in arterialized vein grafts. *FASEB J* 2006 Feb;20(2):398-400. PMID: 16303874.

Pintucci G, Yu PJ, Saponara F, [Kadian-Dodov DL](#), Galloway AC, Mignatti P. PDGF-BB induces vascular smooth muscle cell expression of high molecular weight FGF-2, which accumulates in the nucleus. *J Cell Biochem* 2005;95:1292-300. PMID: 15962299.